PL 8331
Alternative Names: PL-8331Latest Information Update: 21 Apr 2023
At a glance
- Originator Palatin Technologies
- Class Anti-inflammatories; Eye disorder therapies
- Mechanism of Action Melanocortin type 1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Choroidal neovascularisation; Diabetic retinopathy
- Phase Unknown Dry eyes
Most Recent Events
- 18 Apr 2023 Pharmacodynamics data from a preclinical study in Diabetic retinopathy and Uveitis released by Palatin Technologies
- 30 Nov 2021 Palatin Technologies receives patent allowance for method of treating cytokine storm using melanocortin-specific peptide in USA in November 2021
- 29 Sep 2021 PL 8331 is available for licensing as of 29 Sep 2021. http://www.palatin.com